Overview

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital for Special Surgery, New York
Collaborator:
Genentech, Inc.
Treatments:
Rituximab